- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Lunsekimig, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nasal Polyps, Aspirin-exacerbated Respiratory Disease
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Sinusitis With Nasal Polyps and Eosinophilia
- Interventions
- dexpramipexole
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyposis
- Interventions
- DUPIXENT®
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 42 more
- Conditions
- Nasal Polyps
- Interventions
- Depemokimab (GSK3511294), Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Asthma
- Interventions
- Dupilumab, Omalizumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
- Interventions
- Dupilumab - Standard Dose
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- lunsekimig, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- La Jolla, California • Roseville, California • San Diego, California + 11 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Etokimab, Placebo, Mometasone Furoate Nasal Spray
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Canoga Park, California • Roseville, California + 24 more
- Conditions
- Nasal Polyps, Staphylococcus Aureus
- Interventions
- Dupilumab Prefilled Syringe
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Verekitug (UPB-101), Placebo
- Drug
- Lead sponsor
- Upstream Bio Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Newport Beach, California • Roseville, California + 22 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 18
- States / cities
- Long Beach, California • Orange, California • San Diego, California + 15 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- La Mesa, California • Oklahoma City, Oklahoma
- Conditions
- Nasal Polyps
- Interventions
- Depemokimab (GSK3511294), Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
- Conditions
- Smell Loss, Chronic Rhinosinusitis (CRS)
- Interventions
- Smell Training
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- fluticasone nasal spray, Budesonide head upright, Budesonide head forward
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Stratford, Connecticut
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- GB001, Placebo
- Drug
- Lead sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Biological
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- The Bronx, New York